Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience

Meirigeng Qi; Katie Kinzer; Kirstie K. Danielson; Joan Martellotto; Barbara Barbaro; Yong Wang; James T. Bui; Ron C. Gaba; Grace Knuttinen; Raquel Garcia-Roca; Ivo Tzvetanov; Andrew Heitman; Maureen Davis; James J. McGarrigle; Enrico Benedetti; Jose Oberholzer

doi:10.1007/s00592-014-0627-6

Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience

Meirigeng Qi, Katie Kinzer, Kirstie K. Danielson, Joan Martellotto, Barbara Barbaro, Yong Wang, James T. Bui, Ron C. Gaba, Grace Knuttinen, Raquel Garcia-Roca, Ivo Tzvetanov, Andrew Heitman, Maureen Davis, James J. McGarrigle, Enrico Benedetti, Jose Oberholzer

Diagnostic Radiology

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Abstract

This report summarizes a 5-year phase 1/2 allogeneic islet transplantation clinical trial conducted at the University of Illinois at Chicago (UIC). Ten patients were enrolled in this single center, open label, and prospective trial in which patients received 1–3 transplants. The first four subjects underwent islet transplantation with the Edmonton immunosuppressive regimen and the remaining six subjects received the UIC immunosuppressive protocol (Edmonton plus etanercept and exenatide). All 10 patients achieved insulin independence after 1–3 transplants. At 5 years of follow-up, 6 of the initial 10 patients were free of exogenous insulin. During the follow-up period, 7 of the 10 patients maintained positive C-peptide levels and a composite hypoglycemic score of 0. Most patients maintained HbA1c levels <6.0 % (42.1 mmol/mol) and a significantly improved β-score. In conclusion, this study demonstrated long-term islet graft function without using T cell depleting induction, with an encouraging outcome that includes 60 % of patients remaining insulin independent after 5 years of initial transplantation.

Original language	English (US)
Pages (from-to)	833-843
Number of pages	11
Journal	Acta Diabetologica
Volume	51
Issue number	5
DOIs	https://doi.org/10.1007/s00592-014-0627-6
State	Published - Sep 27 2014

Keywords

Immunosuppression
Insulin independence
Islet transplantation
Type 1 diabetes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1007/s00592-014-0627-6

Cite this

Qi, M., Kinzer, K., Danielson, K. K., Martellotto, J., Barbaro, B., Wang, Y., Bui, J. T., Gaba, R. C., Knuttinen, G., Garcia-Roca, R., Tzvetanov, I., Heitman, A., Davis, M., McGarrigle, J. J., Benedetti, E., & Oberholzer, J. (2014). Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience. Acta Diabetologica, 51(5), 833-843. https://doi.org/10.1007/s00592-014-0627-6

Qi, M, Kinzer, K, Danielson, KK, Martellotto, J, Barbaro, B, Wang, Y, Bui, JT, Gaba, RC, Knuttinen, G, Garcia-Roca, R, Tzvetanov, I, Heitman, A, Davis, M, McGarrigle, JJ, Benedetti, E & Oberholzer, J 2014, 'Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience', Acta Diabetologica, vol. 51, no. 5, pp. 833-843. https://doi.org/10.1007/s00592-014-0627-6

@article{4dc900cc54a7438caf5ee95cd351d5dc,

title = "Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience",

abstract = "This report summarizes a 5-year phase 1/2 allogeneic islet transplantation clinical trial conducted at the University of Illinois at Chicago (UIC). Ten patients were enrolled in this single center, open label, and prospective trial in which patients received 1–3 transplants. The first four subjects underwent islet transplantation with the Edmonton immunosuppressive regimen and the remaining six subjects received the UIC immunosuppressive protocol (Edmonton plus etanercept and exenatide). All 10 patients achieved insulin independence after 1–3 transplants. At 5 years of follow-up, 6 of the initial 10 patients were free of exogenous insulin. During the follow-up period, 7 of the 10 patients maintained positive C-peptide levels and a composite hypoglycemic score of 0. Most patients maintained HbA1c levels <6.0 % (42.1 mmol/mol) and a significantly improved β-score. In conclusion, this study demonstrated long-term islet graft function without using T cell depleting induction, with an encouraging outcome that includes 60 % of patients remaining insulin independent after 5 years of initial transplantation.",

keywords = "Immunosuppression, Insulin independence, Islet transplantation, Type 1 diabetes",

author = "Meirigeng Qi and Katie Kinzer and Danielson, {Kirstie K.} and Joan Martellotto and Barbara Barbaro and Yong Wang and Bui, {James T.} and Gaba, {Ron C.} and Grace Knuttinen and Raquel Garcia-Roca and Ivo Tzvetanov and Andrew Heitman and Maureen Davis and McGarrigle, {James J.} and Enrico Benedetti and Jose Oberholzer",

note = "Funding Information: This work was supported by funding from the College of Medicine, University of Illinois at Chicago. J.O. and J. M. were supported by the Islet Cell Resources Center NIH grant (5 U42 RR023245-02), the Christopher Family Foundation, and the Efroymson Foundation. The subjects are evaluated at the UIC Clinical Research Center, which is supported by the University of Illinois at Chicago Center for Clinical and Translational Science (Award Number UL1RR029879) from the National Center for Research Resources. Data acquisition aided by the CITR, Emmes corporation. The islet program was supported by the Chicago Diabetes Project, and the Washington Square Health Foundation. Publisher Copyright: {\textcopyright} 2014, Springer-Verlag Italia.",

year = "2014",

month = sep,

day = "27",

doi = "10.1007/s00592-014-0627-6",

language = "English (US)",

volume = "51",

pages = "833--843",

journal = "Acta Diabetologica",

issn = "0940-5429",

publisher = "Springer-Verlag Italia",

number = "5",

}

TY - JOUR

T1 - Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets

T2 - the UIC experience

AU - Qi, Meirigeng

AU - Kinzer, Katie

AU - Danielson, Kirstie K.

AU - Martellotto, Joan

AU - Barbaro, Barbara

AU - Wang, Yong

AU - Bui, James T.

AU - Gaba, Ron C.

AU - Knuttinen, Grace

AU - Garcia-Roca, Raquel

AU - Tzvetanov, Ivo

AU - Heitman, Andrew

AU - Davis, Maureen

AU - McGarrigle, James J.

AU - Benedetti, Enrico

AU - Oberholzer, Jose

N1 - Funding Information: This work was supported by funding from the College of Medicine, University of Illinois at Chicago. J.O. and J. M. were supported by the Islet Cell Resources Center NIH grant (5 U42 RR023245-02), the Christopher Family Foundation, and the Efroymson Foundation. The subjects are evaluated at the UIC Clinical Research Center, which is supported by the University of Illinois at Chicago Center for Clinical and Translational Science (Award Number UL1RR029879) from the National Center for Research Resources. Data acquisition aided by the CITR, Emmes corporation. The islet program was supported by the Chicago Diabetes Project, and the Washington Square Health Foundation. Publisher Copyright: © 2014, Springer-Verlag Italia.

PY - 2014/9/27

Y1 - 2014/9/27

N2 - This report summarizes a 5-year phase 1/2 allogeneic islet transplantation clinical trial conducted at the University of Illinois at Chicago (UIC). Ten patients were enrolled in this single center, open label, and prospective trial in which patients received 1–3 transplants. The first four subjects underwent islet transplantation with the Edmonton immunosuppressive regimen and the remaining six subjects received the UIC immunosuppressive protocol (Edmonton plus etanercept and exenatide). All 10 patients achieved insulin independence after 1–3 transplants. At 5 years of follow-up, 6 of the initial 10 patients were free of exogenous insulin. During the follow-up period, 7 of the 10 patients maintained positive C-peptide levels and a composite hypoglycemic score of 0. Most patients maintained HbA1c levels <6.0 % (42.1 mmol/mol) and a significantly improved β-score. In conclusion, this study demonstrated long-term islet graft function without using T cell depleting induction, with an encouraging outcome that includes 60 % of patients remaining insulin independent after 5 years of initial transplantation.

AB - This report summarizes a 5-year phase 1/2 allogeneic islet transplantation clinical trial conducted at the University of Illinois at Chicago (UIC). Ten patients were enrolled in this single center, open label, and prospective trial in which patients received 1–3 transplants. The first four subjects underwent islet transplantation with the Edmonton immunosuppressive regimen and the remaining six subjects received the UIC immunosuppressive protocol (Edmonton plus etanercept and exenatide). All 10 patients achieved insulin independence after 1–3 transplants. At 5 years of follow-up, 6 of the initial 10 patients were free of exogenous insulin. During the follow-up period, 7 of the 10 patients maintained positive C-peptide levels and a composite hypoglycemic score of 0. Most patients maintained HbA1c levels <6.0 % (42.1 mmol/mol) and a significantly improved β-score. In conclusion, this study demonstrated long-term islet graft function without using T cell depleting induction, with an encouraging outcome that includes 60 % of patients remaining insulin independent after 5 years of initial transplantation.

KW - Immunosuppression

KW - Insulin independence

KW - Islet transplantation

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84919484780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919484780&partnerID=8YFLogxK

U2 - 10.1007/s00592-014-0627-6

DO - 10.1007/s00592-014-0627-6

M3 - Article

C2 - 25034311

AN - SCOPUS:84919484780

SN - 0940-5429

VL - 51

SP - 833

EP - 843

JO - Acta Diabetologica

JF - Acta Diabetologica

IS - 5

ER -

Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this